EMD-17170
Local refinement of the SARS-CoV-2 Spike RBD bound to TMEM106B
EMD-17170
Single-particle4.83 Å
Deposition: 20/04/2023Map released: 19/07/2023
Last modified: 16/08/2023
Sample Organism:
Homo sapiens,
Severe acute respiratory syndrome coronavirus 2,
Severe acute respiratory syndrome coronavirus 2
Sample: Trimeric SARS-CoV-2 Spike bound to one molecule of TMEM106B
Deposition Authors: CHEREPANOV P
Sample: Trimeric SARS-CoV-2 Spike bound to one molecule of TMEM106B
Deposition Authors: CHEREPANOV P
TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry.
Baggen J,
Jacquemyn M ,
Persoons L ,
Vanstreels E,
Pye VE,
Wrobel AG ,
Calvaresi V ,
Martin SR,
Roustan C,
Cronin NB,
Reading E ,
Thibaut HJ ,
Vercruysse T,
Maes P,
De Smet F ,
Yee A,
Nivitchanyong T,
Roell M,
Franco-Hernandez N,
Rhinn H,
Mamchak AA,
Ah Young-Chapon M,
Brown E,
Cherepanov P ,
Daelemans D
(2023) Cell , 186 , 3427 - 3442.e22
,
Persoons L ,
Vanstreels E,
Pye VE,
Wrobel AG ,
Calvaresi V ,
Martin SR,
Roustan C,
Cronin NB,
Reading E ,
Thibaut HJ ,
Vercruysse T,
Maes P,
De Smet F ,
Yee A,
Nivitchanyong T,
Roell M,
Franco-Hernandez N,
Rhinn H,
Mamchak AA,
Ah Young-Chapon M,
Brown E,
Cherepanov P ,
Daelemans D
(2023) Cell , 186 , 3427 - 3442.e22
Grant Support:
- Wellcome Trust: FC001061 (United Kingdom)
- Medical Research Council (MRC, United Kingdom): FC001061 (United Kingdom)
- Cancer Research UK: FC001061 (United Kingdom)
- Wellcome Trust: 206175/Z/17/Z (United Kingdom)